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Activation of Src, which has an intrinsic protein tyrosine kinase activity, has been demonstrated in many human tumours, such
as colorectal and breast cancers, and is closely associated with the pathogenesis and metastatic potential of these cancers. In
this study, we have examined the effect of activated Src on the sensitivity to taxotere, an anticancer drug targeting
microtubules, using v-src-transfected HAG-1 human gall bladder epithelial cells. As compared with parental HAG-1 cell line, v-
src-transfected HAG/src3-1 cells became 5.9 and 7.0-fold sensitive to taxotere for 2 and 24-h exposure, respectively. By
contrast, HAG-1 cells transfected with activated Ras, which acts downstream of Src, acquired approximately 2.5*4.8-fold
taxotere resistance. The taxotere sensitivity in HAG/src3-1 cells was reversed, if not completely, by herbimycin A, a speciﬁc
inhibitor of Src family protein tyrosine kinase, indicating that Src protein tyrosine kinase augments sensitivity to taxotere.
Treatment of HAG/src3-1 cells with taxotere resulted in phosphorylation of Bcl-2 and subsequent induction of apoptotic cell
death, whereas neither Bcl-2 phosphorylation nor apoptosis occurred in parental or c-H-ras-transfected HAG-1 cells.
Interestingly, the Bcl-2 protein is overexpressed in v-src-transfected cell line, compared to those in parental or Ras-transfected
cell line. Treatment of HAG/src3-1 cells with herbimycin A signiﬁcantly reduced the expression and phosphorylation of Bcl-2,
and abrogated taxotere-induced apoptosis, suggesting a potential role for Src protein tyrosine kinase in the taxotere-induced
apoptotic events. H-7, a protein kinase C inhibitor and wortmannin, a phosphatidylinositol-3 kinase (PI-3 kinase) inhibitor,
neither altered taxotere sensitivity nor inhibited taxotere-induced apoptosis in these cells. These data indicate that the ability
of activated Src to increase taxotere sensitivity would be mediated by apoptotic events occurring through Src to downstream
signal transduction pathways toward Bcl-2 phosphorylation, but not by activated Ras, PI-3 kinase or protein kinase C.
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Taxanes, the novel chemotherapeutic drugs, have unique mechan-
isms of action that promote tubulin polymerization as well as the
formation and stabilization of microtubules, thus blocking cell
cycle at the metaphase to anaphase transition (Schiff et al, 1979;
Ringel and Horwitz, 1991; Horwitz, 1992). Although the arrest of
cells in the G2-M phase of the cell cycle correlates with taxane-
induced apoptosis (Woods et al, 1995), the precise mechanism of
apoptotic action of taxanes still remains unclear. The phosphoryla-
tion of Bcl-2, a prototype of a related group of proteins implicated
in regulating apototic cell death (Reed, 1994), has been reported as
a potential cause of taxane-induced apoptosis (Haldar et al, 1995,
1996, 1997). Certain members of the Bcl-2 family are proapoptotic
(i.e. Bcl-Xs, Bad, Bax), while others are antiapoptotic (i.e. Bcl-2,
Bcl-XL, Mcl-1) (Oltvai et al, 1993; Reed, 1997). Several studies have
demonstrated that Bcl-2 phosphorylation can be speciﬁcally
induced by drugs targeting microtubules, whereas this effect is
not seen by DNA-damaging agents (Haldar et al, 1997). The Bcl-
2 phosphorylation at serine residues leads to loss of Bcl-2 anti-
apoptotic function (Haldar et al, 1995) by inhibiting its binding
to the proapoptotic Bax protein (Haldar et al, 1996). Thus, it is
suggested that prevention of depolymerization of cellular microtu-
bules by taxanes causes phosphorylation of Bcl-2, thereby
abrogating the normal anti-apoptotic function of Bcl-2 and initiat-
ing the apoptotic program in the cycling cancer cells.
Certain oncogenes, such as v-src, activate both mitogenic and
survival signaling pathways. v-Src is a mutationally activated form
of the non-receptor tyrosine kinase c-Src, and c-Src has been
shown to be activated frequently in human cancers, such as breast
(Hennipman et al, 1989; Ottenhoff-Kalff et al, 1992), colon (Bolen
et al, 1987; Cartwright et al, 1990; Talamonti et al, 1993), skin
(Barnekow et al, 1989), bladder (Fanning et al, 1992) and pancreas
cancers (Lutz et al, 1998). Speciﬁcally, c-Src has been found to be
highly activated in colon cancer metastasized to the liver (Mao et
al, 1997) and mutation in the regulatory domain of c-Src has been
reported as a mechanism of Src activation in human colon cancer
(Irby et al, 1999). Although a number of signal transduction path-
ways toward Bcl-2 phosphorylation have been reported as an
apoptotic mechanism induced by taxanes (Wang et al, 1999), the
role of Src in these processes has yet to be determined. Src trans-
duces a variety of signals to downstream signal transduction
cascades including Ras (Brown and Cooper, 1996). Thus, activation
of Src may potentially affect the apoptotic events induced by
taxanes, because several lines of evidence suggest that apoptosis
induced by those microtubule-targeting agents require the Ras/c-
Raf-1/Bcl-2 pathway (Blagosklonny et al, 1996, 1997, 1999).
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tion, and the sensitivity to taxanes has not been studied.
Recently, we have studied whether activated Src induces
chemoresistance by evaluating alterations of drug sensitivity in
human HAG-1 gall bladder epithelial cells transfected with v-src
oncogene and determined the mechanism of drug resistance. We
have found that v-src induces resistance to cisplatin (CDDP)
through activation of the repair of CDDP-induced DNA damage
(Masumoto et al, 1999). In continuing these studies, we have
recently found that v-Src induces signiﬁcant sensitivity to taxotere,
a semi-synthetic taxol analogue. In this report, we have investigated
the cellular and molecular mechanism(s) whereby Src induces taxo-
tere sensitivity, with special reference to taxotere-induced apoptosis
and Bcl-2 phosphorylation, using v-src-transfected HAG-1 human
epithelial cells. We found that Src tyrosine kinase augments taxo-
tere-induced apoptosis by enhancing Bcl-2 expression and
phosphorylation.
MATERIALS AND METHODS
Cells and cultures and chemicals
HAG-1 is a human epithelial cell line derived from a moderately
differentiated adenocarcinoma of the gallbladder (Nakano et al,
1994). No mutations and ampliﬁcations of H-, K-, or N-ras genes
have been detected in this cell line. The HAG-1 cells do not grow
in soft agar and have remained non-tumorigenic in nude mice.
HAG/ras5-1 cells were obtained by transfecting HAG-1 parental
cells with activated c-H-ras. The H-ras-transfected clone cannot
grow in soft agar despite expression of activated p21
ras oncopro-
tein, whereas HAG/src3-1 cells, obtained by transfection of the
pSV2/v-src into HAG-1 cells, express p60
v-src protein, grow in soft
agar and are highly tumorigenic (Tatsumoto et al, 1995). Indivi-
dual cells were cultured at 378C in Dulbecco’s minimum
essential medium (DMEM, Nissui, Tokyo, Japan) supplemented
with 10% heat-inactivated foetal bovine serum (FBS, Gibco, Grand
Island, NY, USA) in a humidiﬁed atmosphere of 5% CO2 and 95%
air.
Wortmannin and Herbimycin A (HA) were obtained from
Wako Chemicals (Osaka, Japan). H-7 [1-(5-isoquinolinylsulfo-
nyl)-2-methylpiperazine] were obtained from Sigma (St Louis,
MO, USA). H-7 was dissolved in distilled water as 10 mM stock
solution and stored at 48C. Taxotere (Docetaxel) was a kind gift
from Rhone-Poulenc Rorer (Tokyo, Japan). Taxotere, HA and
wortmannin were dissolved in 100% demethyl sulphoxide (DMSO)
as 50006 stock solutions and aliquots were frozen. All solutions
were prepared fresh by diluting with DMEM on the day of use.
The ﬁnal concentration of DMSO for all experiments and treat-
ments (including controls, where no drug was added) was
maintained at less than 0.02%. These conditions were found to
be non-cytotoxic.
Cell-survival assay
Cells were seeded in triplicate in 4 ml of complete medium into
60-mm tissue culture dishes (Falcon 3002; Oxnard, CA, USA) such
that the control cultures did not reach conﬂuence, in order to
avoid the inﬂuence of density inhibition of cell growth on cytotoxi-
city. The cells were incubated overnight to allow attachment to the
plastic prior to administration of the drug, and exposed to various
concentrations of taxotere for 2 or 24 h. Following each taxotere
treatment, the cells were washed twice with phosphate buffered
saline (PBS, Nissui, Tokyo, Japan) and the medium was replaced
with fresh complete medium for an additional 3 days. Then the
medium was replaced with complete medium. The cells were
continuously cultured after drug treatment for 7 days. Trypsinized
cells were counted using a Coulter counter (model ID; Hialeah, FL,
USA). The percentage of cell growth for taxotere was calculated by
dividing the number of cells in the drug-treated culture by the
number of cells in the culture not exposed to the drug. For each
cell line, at least ﬁve independent experiments with triplicate
samples were performed.
Treatment with Src tyrosine kinase inhibitor
Cells were plated in triplicate in 4 ml of complete medium in 60-
mm tissue culture dishes, allowed to attach overnight and then
incubated with various concentrations of taxotere for 2-h with or
without HA, a well characterized inhibitor of Src family tyrosine
kinase (Fukazawa et al, 1991). After each treatment, the cells were
washed twice with PBS, and the medium was replaced with fresh
complete medium with or without HA for an additional 72 h.
The cell number was determined on day 7. The percentage of cell
growth was compared with that of treatment with the drug alone.
For both cell lines, parental HAG-1 and v-src-transfected HAG/
src3-1, ﬁve independent experiments with triplicate samples were
performed.
Treatment with protein kinase C and phosphatidylinositol-
3 kinase inhibitors
To examine the role of protein kinase C (PKC) in the cytotoxicity
for taxotere, the cells were exposed to various concentrations of
taxotere for 2 h with or without H-7, a PKC inhibitor (Hidaka
et al, 1984). The medium was replaced with fresh complete
medium, but H-7 treatment was continued for an additional
72 h. The cell number was determined on day 7. To study the role
of phosphatidylinositol-3 kinase (PI-3 kinase) in the cytotoxicity
for taxotere, cells were preincubated for 30 min with wortmannin,
an inhibitor of PI-3 kinase (Yano et al, 1993), immediately before
taxotere treatment, and treated with various concentrations of
taxotere for 2 h. The number of cells was determined on day 7
after treatment with taxotere. The percentage of cell growth was
compared with that of treatment with taxotere alone. For each
treatment, three independent experiments with triplicate samples
were performed.
Immunoprecipitation and Western blot analysis
Exponentially growing cells (approximately 5610
6 cells) were trea-
ted for 24 h with taxotere, then washed twice in ice-cold PBS. At
various points in time, ﬂoating and trypsinized adherent cells were
combined, and cells were lysed for 30 min on ice in lysis buffer
containing 50 mM Tris-Cl (pH 7.2), 150 mM NaCl, 2 mM EDTA,
0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, protein
tyrosine phosphatase inhibitor (1 mM Na3VO4), and protease inhi-
bitors (1 mM phenylmethylsulfonyl ﬂuoride, 20 mgm l
71 aprotinin,
20 mgm l
71 leupeptin, and 20 mgm l
71 pepstatin). After centrifu-
gation at 15000 r.p.m. at 48C for 15 min, supernatant proteins
were immunoprecipitated using protein G-Sepharose 4B (Sigma,
St Louis, MO, USA) preconjugated overnight at 48C with mouse
monoclonal antibody to Bcl-2 (Genosys, Pampisford, Cambridge-
shire, UK). The Sepharose beads were isolated by centrifugation
at 12000 r.p.m. for 2 min. The immuno-precipitates were then
washed four times with ice-cold lysis buffer, resuspended in
SDS–PAGE sample buffer, boiled for 5 min, and pelleted by
centrifugation at 12000 r.p.m. for 2 min. The protein content of
the supernatant was determined with the protein assay kit (Bio-
Rad, Hercules, CA, USA), according to manufacturer’s instructions.
Equal amounts of protein from each sample were loaded onto 12%
SDS–PAGE and electrophoretically transferred to nitrocellulose
membrane (type Hybond ECL; Amersham, Japan). Nonspeciﬁc
binding on the nitrocellulose membrane was minimized with
blocking buffer containing 3% bovine serum albumin (BSA, Sigma,
St Louis, MO, USA) in Tris-buffered saline. The proteins were
probed with primary antibody (the mouse monoclonal anti-Bcl-2
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antibody, horse radish peroxidase-conjugated goat anti-mouse
IgG antibody (ICN Biomedicals/Cappel, Aurora, OH, USA) for
1 h at room temperature. The protein bands were visualized using
an enhanced chemiluminescence system (ECL; Amersham, Japan).
Taxotere-induced apoptosis by DNA fragmentation assay
Exponentially growing cells were treated with 100 nM taxotere
for 24 h, washed twice with PBS, and incubated for an addi-
tional 24 h in drug-free complete medium. Floating and
trypsinized adherent cells were combined. Low-molecular weight
genomic DNA was extracted from *5610
6 cells by a guanidine
thiocyanate method using Sepa Gene Kit (Sanko Junyaku,
Tokyo, Japan) and precipitated with isopropanol. The ﬁnal
concentration of DNA was determined by UV absorbance at
260 nm (Beckman DU-530 spectrophotometer, Fullerton, CA,
USA). Approximately 20 mg of DNA were loaded on each lane
of 2% agarose (Sigma, St Louis, MO, USA) gels. DNA was
stained with ethidium bromide (1 mgm l
71) and visualized
under electronic UV transilluminator (Ultra-Lum, Carson, CA,
USA) using a CCD black-and-white video camera module
(Sony, Tokyo, Japan).
Intracellular taxotere content
Exponentially growing cells (*1610
7 cells) were treated with
55.0 nM taxotere for 2-h (IC50 values for parental HAG-1 cells),
and then washed three times with ice-cold PBS. After trypsiniza-
tion, cells were dissolved in 1 ml of ice-cold PBS, lysed by
sonication (Branson Ultrasonics, Danbury, CT, USA), and centri-
fuged (Himac centrifuge; Hitachi, Tokyo, Japan). The
supernatants were frozen at 7808C and later analyzed for taxotere
concentration by a rapid reversed phase HPLC method as
described (Rouini et al, 1998). The intracellular concentration
was expressed as relative values per 10
6 cells.
Statistical analysis
The data were analyzed by the Mann–Whitney U-test for statistical
signiﬁcance of the difference between groups. A P value of 50.01
was considered to indicate statistical signiﬁcance.
RESULTS
Chemosensitivity proﬁle
To determine whether activated Src PTK (p60
v-src) affects drug
cytotoxicity, we examined the taxotere sensitivity in v-src-trans-
fected human gall bladder epithelial cells (HAG/src3-1), and
compared their IC50 values with those of parental HAG-1 cell line.
The respective IC50 values of taxotere for 2 and 24-h exposures
were 55.4+1.86 nM and 5.05+0.25 nM for HAG-1 parental cells,
and 9.47+0.32 nM and 0.725+0.017 nM for HAG/src3-1 cells,
indicating approximately 6–7-fold increase in sensitivity to taxo-
tere. By contrast, HAG-1 cells transfected with activated H-ras
(HAG/ras5-1) exhibited the IC50 value of 263.7+7.22 nM and
12.7+0.20 nM for 2 and 24-h exposure, respectively, indicating
acquisition of approximately 2.5–4.7-fold taxotere resistance.
Effects of protein kinase inhibitor on taxotere-induced
cytotoxicity
To determine whether p60
v-src PTK activity is required for sensitiv-
ity to taxotere in v-src-transfected cells, we studied the effect of HA
on the taxotere sensitivity in parental HAG-1 and HAG/src3-1 cell
lines. Combined treatment with taxotere and HA did not alter the
sensitivity to taxotere in parental cells, but signiﬁcantly reduced
taxotere sensitivity in v-src-transfected cell line, in a dose-depen-
dent manner, and sensitivity was reversed, if not completely, at
the concentration of 100 ng ml
71 of HA (Figure 1). To determine
whether PI-3 kinase and/or PKC signal transduction pathways are
involved in the mechanism of taxotere-induced sensitivity, we
examined the effect of PKC inhibitor, H-7, and the effect of PI-3
kinase inhibitor, wortmannin, on taxotere cytotoxicity. Neither
H-7 nor wortmannin at the non-toxic maximal concentration
(20 nM) affected the cytotoxicity of taxotere in both parental
HAG-1 and HAG/src3-1 cell lines (data not shown). These data
indicate that taxotere sensitivity observed in HAG/src3-1 cells is
partly induced by Src tyrosine kinase, but not by either PI-3 kinase
or PKC.
Dose-dependent effect of taxotere on Bcl-2
phosphorylation and inter-nucleosomal DNA
fragmentation
The slower-migrating form of Bcl-2 was evident in HAG/src3-1
cells exposed to taxotere concentrations as low as 1 nM for 24 h,
but not in DMSO-treated cells as a control, and a maximal effect
was observed with a 100 nM taxotere concentration (Figure 2A).
This modiﬁed form of Bcl-2 has been shown to represent phos-
phorylated form of the Bcl-2 protein (Haldar et al, 1995). In
parallel with Bcl-2 phosphorylation, taxotere-induced apoptosis,
as determined by DNA fragmentation assay, was observed in
HAG/src3-1 cells incubated with 100 nM taxotere for 24 h (Figure
2B). Agarose electrophoresis of DNA extracted from these cells
showed a characteristic laddering pattern of oligonucleosomal
DNA fragments resulting from internucleosomal chromatin clea-
vage by endogenous endonucleases.
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Figure 1 Effects of herbimycin A (HA) on the cytotoxicity of taxotere in
parental HAG-1 and HAG/src3-1cells. Cells were treated with various con-
centrations of taxotere for 2 h and incubated for an additional 3 days, with
or without HA. Cell survival was determined on day 7. Cytotoxicity curves
of taxotere for HAG-1 (&) and HAG/src3-1 (*) without HA treatment.
HAG-1 cells co-treated with taxotere and 100 ng ml
71 of HA (^). HAG/
src3-1 cells co-treated with taxotere and 10 (~), 50 (6) or 100 (!)
ng ml
71 of HA. The data represent the means from ﬁve independent ex-
periments. bars, s.d.. The s.d. for all points without error bars is less than 5%.
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phosphorylation and inter-nucleosomal DNA
fragmentation
Next we examined kinetics of Bcl-2 phosphorylation in HAG/src3-
1 cells. The phosphorylated form of Bcl-2 reached a maximum
with a 100 nM taxotere concentration at 24-h post-treatment,
but declined drastically at 48 h (Figure 3A). In accordance with
Bcl-2 phosphorylation, the amount of oligonucleosomal DNA
fragments increased with incubation time after taxotere treatment,
and a maximal effect was observed with a 100 nM taxotere
concentration at 48 h post-treatment (Figure 3B). At this time,
only internucleosomal DNA fragments were present due to the
complete apoptotic death of total cells. These data indicate that
apoptotic events may be preceded by phosphorylation of Bcl-2.
The observed decline in Bcl-2 phosphorylated form at 48 h
post-treatment could be probably due to its degradation in the
process of apoptotic cell death.
Taxotere induces Bcl-2 phosphorylation and
internucleosomal DNA fragmentation in v-src-transfected
HAG/src3-1 cells
We tested whether there are any differences between Src and Ras
signalling pathways in taxotere-induced apoptosis. The v-src-trans-
fected HAG/src3-1 cells highly expressed Bcl-2, and
phosphorylated form of Bcl-2 was evident by the treatment of
100 nM taxotere (Figure 4A). By contrast, HAG-1 and HAG/
ras5-1 slightly expressed Bcl-2, and failed to induce phosphoryla-
tion of Bcl-2 in the presence of taxotere (Figure 4A).
Correspondingly, DNA fragmentation typical of apoptosis was
observed only in Bcl-2-expressing HAG/src3-1 cells, but not in
HAG-1 or HAG/ras5-1 cell lines (Figure 4B). These data indicate
that v-Src, but not activated Ras, augments steady state levels of
Bcl-2 expression and induces apoptosis through phosphorylation
of Bcl-2.
Effect of herbimycin A on the expression and
phosphorylation status of Bcl-2 and internucleosomal DNA
fragmentation
To determine whether Src PTK activity is required for taxotere-
induced Bcl-2 phosphorylation and apoptosis, we examined the
effect of HA on the expression and phosphorylation status of
Bcl-2 and internucleosomal DNA fragmentation in HAG/src3-1
cells. Combined treatment with 100 nM taxotere and 10 ng ml
71
of HA markedly reduced expression of Bcl-2 and taxotere-induced
phosphorylation of Bcl-2 (Figure 5A), as well as internucleosomal
DNA fragmentation (Figure 5B). At the concentration of
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Figure 2 Dose-dependent effects of taxotere on Bcl-2 phosphorylation
(A) and internucleosomal DNA fragmentation (B). (A) Western blot ana-
lysis of total proteins extracted from DMSO- or taxotere-treated HAG/
src3-1 cells. The cells were treated either with vehicle solvent alone or with
several taxotere concentrations (1–100 nM) for 24 h. After treatment, to-
tal cellular proteins were isolated as described in Materials and Methods.
Equal amounts of protein were fractionated by 12% SDS–PAGE, trans-
ferred to nitrocellulose ﬁlter, and then blotted by monoclonal antibody
against Bcl-2 protein. The arrows indicate the position of unphosphorylated
and phosphorylated (modiﬁed) Bcl-2. Representative blots are shown. (B)
Agarose electrophoresis of total DNA isolated from HAG/src3-1 cells fol-
lowing DMSO or taxotere exposure. The cells were treated either with ve-
hicle solvent alone or with various concentrations of taxotere (5–100 nM)
for 24 h and incubated for an additional 24 h in drug-free medium. Lane M,
100-bp DNA ladder.
100 nM  Taxotere
0            3            6          12          24          48   (h)
26 kDa —
modified Bcl-2
Bcl-2
A
B 100 nM Taxotere
M        0        6        12       24     48      (h)
Figure 3 Kinetics of taxotere-induced Bcl-2 phosphorylation (A) and in-
ternucleosomal DNA fragmentation (B). The cells were exposed to
100 nM taxotere for 24-h and incubated in drug-free medium for indicated
times. (A) Immunoblot of the total protein extract. Equivalent amounts of
immunoprecipitates from HAG/src3-1 cells were subjected to 12% SDS–
PAGE, followed by electroblotting to nitrocellulose, and then blotting by
anti-Bcl-2 antibody. Arrows, unmodiﬁed and modiﬁed forms of Bcl-2. (B)
Representative agarose gel of DNA isolated from HAG/src3-1 cells treated
with 100 nM taxotere. Lane M, 100-bp DNA ladder.
A
B
modified Bcl-2
Bcl-2
HAG-1 HAG/ras5-1 HAG/src3-1
26 kDa —
HAG-1 HAG/ras5-1 HAG/src3-1
DMSO TXT DMSO TXT DMSO TXT
M DMSO TXT DMSO TXT DMSO TXT
Figure 4 Taxotere induces phosphorylation of Bcl-2 and apoptosis only
in v-src-transfected HAG/src3-1 cells. (A) Immunoblot analyses of total
proteins extracted from DMSO-treated or taxotere-treated parental
HAG-1, HAG/ras5-1 and HAG/src3-1 cell lines were carried out as de-
scribed in Materials and Methods. All 3 cell lines were incubated with ve-
hicle solvent alone or 100 nM taxotere for 24 h. Equal amounts of total
protein extracts were electrophoresed on 12% SDS–PAGE, followed by
transblotting to nitrocellulose membranes, and immunoblotted using a
monoclonal antibody to Bcl-2. Arrows, unmodiﬁed and phosphorylated
forms of Bcl-2. (B) Agarose gel electrophoresis of total DNA isolated from
HAG/src3-1 cells treated with DMSO or taxotere. The cells were treated
with vehicle solvent alone or 100 nM taxotere for 24 h, incubated for an
additional 24 h in drug-free medium, and subjected to agarose gel electro-
phoresis. Lane M, 100-bp DNA ladder.
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71 of HA, the inhibition was almost complete, resulting
in disappearance of both forms of Bcl-2 (Figure 5A). Similarly,
taxotere-induced apoptosis, as determined by DNA fragmentation
assay, was completely inhibited after co-treatment with 100 nM
taxotere and 100 ng ml
71 of HA (Figure 5B). These ﬁndings indi-
cate that Src tyrosine kinase activity is associated with Bcl-2
expression, its phosphorylation and apoptotic cell death.
Intracellular taxotere content
To determine whether there are any differences of intracelluar
taxotere content between taxotere-sensitive and taxotere-resistant
cell lines, we directly measured cellular taxotere concentrations
after treatment of cells with 55 nM taxotere for 2-h (IC50 values
for parental HAG-1 cells). The resultant taxotere concentrations
were 15.1+0.96 and 12.2+1.05 pM per 10
6 parental HAG-1 and
10
6 HAG/src3-1 cells, respectively, being not signiﬁcantly different
between these cell lines (P=0.20). These results indicate that intra-
cellular drug accumulation does not play a role in taxotere-induced
sensitivity in HAG/src3-1 cells.
DISCUSSION
In the present study, we found that transfection of v-src renders
human gall bladder epithelial HAG-1 cells sensitive to taxotere
through augmentation of apoptotic cell death. A signiﬁcant reduc-
tion of apoptosis was observed upon treatment with HA, a speciﬁc
inhibitor of Src-family PTKs, suggesting that susceptibility to taxo-
tere-induced apoptotic cell death is mediated by the activation of
Src PTK. This is the ﬁrst report demonstrating a direct association
between taxotere-induced apoptosis and Src PTK activity. The
intracellular taxotere contents were virtually identical between
those cell lines, indicating that the intracellular drug accumulation
does not explain the difference of taxotere sensitivity. v-Src, which
has an intrinsic constitutively activated tyrosine kinase activity due
to the lack of a negative regulatory domain, has been shown to
phosphorylate a number of intracellular substrates on tyrosine resi-
due (Brown and Cooper, 1996) and transduce signal throughout
the cell to the nucleus. Among those signal transducers, Ras, which
acts downstream of Src, may not be a cause of taxotere sensitivity,
because activated Ras failed to induce taxotere sensitivity. Likewise,
both PI-3 kinase and PKC pathways, which are activated directly or
indirectly by v-Src through the association of SH2 and SH3
domains, appear not to be involved in the sensitivity mechanism,
because inhibitors of these signal transduction pathways did not
alter the sensitivity to taxotere. Although the data were not shown,
Src also sensitized HAG-1 cells to taxol, another clinically useful
taxane compound. Taxol induced apoptotic cell death at nearly
100-fold higher concentrations than taxotere. These data strongly
suggest that the ability of activated Src to induce taxane sensitivity
would be mediated by the augmentation of apoptosis through Src
to downstream signal transduction pathways distinct from either
Ras, PI-3 kinase, or PKC pathway.
Studies using taxanes have shown that Bcl-2 can be phos-
phorylated by taxanes at speciﬁc serine residues and that Bcl-2
phosphorylation is associated with loss of its anti-apoptotic func-
tion (Haldar et al, 1995; Srivastava et al, 1999). Therefore, we
studied the effect of taxotere on phosphorylation status of Bcl-
2. We have found that taxotere induces phosphorylation of
Bcl-2 only in v-src-transfected HAG/src3-1 cells, but not in
parental or c-H-ras-transfected HAG-1 cells. Consistent with
previous observations, Bcl-2 phosphorylation is detected in the
cells that underwent apoptotic cell death. According to the time
course experiments, Bcl-2 phosphorylation precedes apoptotic
events. Moreover, we demonstrated that HA abrogates taxotere-
induced cell death and prevents Bcl-2 phosphorylation. These
data suggest that Src tyrosine kinase augments taxotere-induced
apoptosis presumably through phosphorylation of Bcl-2. At
present, we do not know the precise mechanism whereby Src
augments taxotere-induced phosphorylation of Bcl-2. However,
several studies have suggested a role of Raf-1 serine/threonine
kinase in the Bcl-2 phosphorylation following taxol treatment
(Blagosklonny et al, 1996, 1997, 1999). Inhibition of RNA or
protein synthesis prevents Raf-1 activation and Bcl-2 phosphory-
lation, suggesting that an intermediate protein(s) acts upstream
of Raf-1 in this microtubule damage-activating pathway (Blagosk-
lonny et al, 1997). Other study, however, has not conﬁrmed this
observation. Ibrado et al (1997) reported that taxol-induced
apoptosis in HL-60 human myeloid leukaemia cells was not asso-
ciated with activation of Raf-1. Our ﬁnding that activated Ras,
which acts upstream of Raf-1, failed to induce taxotere sensitiv-
ity, suggest that involvement of Raf-1 kinase in taxotere-induced
apoptotic signaling pathways is unlikely in v-src-transfected
HAG-1 cells.
We have found that Bcl-2 is overexpressed only in v-src-trans-
formed HAG/src3-1 cell line. This overexpression is reduced by
Src tyrosine kinase inhibitor, suggesting a possibility that Src tyro-
sine kinase may enhance transcription of bcl-2. In this regard, we
have recently shown that the signal transducer and activator of
transcription 3 (STAT3) is constitutively activated in these HAG/
src3-1 cells (Murakami et al, 1998). Therefore, we have hypothe-
sized that STAT3 may promote the transcription of certain
factors associated with Bcl-2 expression. Accordingly, it has been
reported that decreased ability of STAT3 to bind DNA precedes
decreased Bcl-2 expression and induction of apoptosis (Nielsen et
al, 1999), indicating the involvement of STAT3 in the transcription
of Bcl-2. The effect of dominant negative Stat3 on the Bcl-2 expres-
sion is currently under way. Moreover, the ﬁnding that taxotere
induces apoptosis only in cells over-expressing Bcl-2 suggests that
the apoptotic response of these cells to taxotere may depend on
their Bcl-2 expression. Therefore, it will be important to determine
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Figure 5 Effect of Src tyrosine kinase inhibitor, herbimycin A (HA) on
the taxotere-induced phosphorylation status of Bcl-2 and internucleosomal
DNA fragmentation. (A) Western blots of treated cell lysates were done
as described in Materials and Methods. The HAG/src3-1 cells were treated
with either DMSO (vehicle solvent), 100 nM taxotere, taxotere+10 ng/ml
HA, or taxotere+100 ng ml
71 HA, for 24 h. Equivalent amounts of immu-
noprecipitates of anti-Bcl-2 antibody were separated by 12% SDS–PAGE,
transferred on nitrocellulose sheet by electroblotting and then immuno-
blotted by monoclonal antibody against Bcl-2. The arrows indicate the
position of unmodiﬁed and modiﬁed (phosphorylated) Bcl-2. (B) Repre-
sentative agarose gel of DNA isolated from HAG/src3-1 cells. Cells were
exposed to either DMSO+100 ng ml
71 HA, 100 nM taxotere, or taxo-
tere+HA for 24 h, incubated for an additional 24 h in drug-free medium,
and subjected to agarose gel electrophoresis. Lane M, 100-bp DNA ladder.
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sensitive to the apoptotic action of taxotere.
In this study, we have demonstrated that v-src oncogene induces
sensitivity to taxotere through Bcl-2 phosphorylation and apopto-
sis. By contrast, using the same cell line, we have recently shown
that v-src induces cisplatin resistance through augmentation of
the repair of CDDP-induced DNA cross-links (Masumoto et al,
1999). Therefore, taxane sensitivity and cisplatin resistance may
be induced by the common signal transduction mechanism acti-
vated by Src tyrosine kinase. These data indicate that Src
tyrosine kinase activity induces diverse effects on the chemosensi-
tivity depending on the mechanism of action of anticancer
agents. Several studies have demonstrated that Bcl-2 phosphoryla-
tion can be speciﬁcally induced by drugs that affect microtubule
depolymerization or prevent microtubule assembly, whereas this
effect is not seen by DNA damaging agents, such as cisplatin
(Haldar et al, 1995, 1997). Therefore, apoptotic pathways induced
by taxanes would be qualitatively different from those induced by
cisplatin. There might be many signal transduction pathways of
Src; some of them augments taxanes-induced apoptosis, and the
others can prevent cell death by increasing the repair capacity of
cisplatin-induced DNA damage. This hypothesis may explain the
basis for the collateral sensitivity of cisplatin-resistant cell lines to
taxol. Several studies have previously shown that cell lines resistant
to cisplatin acquire taxol sensitivity (Perego et al, 1998; Judson et
al, 1999). For instance, ovarian cell lines resistant to CDDP (C-
13 and A2780CP) showed about 10-fold increase in sensitivity to
taxol when compared to their respective parental cells, 2008 and
A2780 (Judson et al, 1999). Similar observations have been noted
in clinical studies which demonstrated that patients with cispla-
tin-resistant gynaecological cancers show an enhanced response
to taxol (Woo et al, 1996).
In summary, human HAG-1 gall bladder adenocarcinoma cells
are sensitized to apoptosis by taxotere through Bcl-2 phosphoryla-
tion as a consequence of activation of Src PTK. Therefore, it will be
important to know the activation of Src before treatment, thus
providing not only an opportunity to use therapeutic agents
against more reﬁned targeting, but also the advantage for selecting
anticancer agents in individual cancers.
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